SCHEMBL12329374

SCHEMBL12329374

BCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 7/20 0.56
▸ HTR2A P28223 7/20 0.52
▸ TAAR1 Q96RJ0 1/20 0.48
▸ KCNH2 Q12809 3/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ ADRA2A P08913 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ SMPD1 P17405 1/20 0.45
▸ DRD1 P21728 1/20 0.45
▸ TBXA2R P21731 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ SLC6A4 P31645 1/20 0.45
▸ ADRA1A P35348 1/20 0.45
▸ OPRM1 P35372 1/20 0.45
▸ DRD3 P35462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290730 0.82 HRH1 (0.68) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL6661940 0.80 HRH1 (0.61) HRH1HTR2ATAAR1SIGMAR1
SCHEMBL2732016 0.79 HRH1 (0.65) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL27321444 0.79 HRH1 (0.65) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL844862 0.79 HRH1 (0.65) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL8852211 0.77 HTR2A (0.52) HRH1HTR2ATAAR1LMNATDP1
SCHEMBL9073997 0.77 HRH1 (0.71) HRH1HTR2ATAAR1KCNH2CHRM2
SCHEMBL4811034 0.72 HRH1 (0.56) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL2551931 0.72 HRH1 (0.56) HRH1HTR2ATAAR1KCNH2CYP3A4
SCHEMBL863751 0.72 HRH1 (0.56) HRH1HTR2ATAAR1KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366698-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor Galapagos SAS (FR) 2011-09-21 — — EP disclosed
US-20090054451-A1 Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity EUROSCREEN S.A. (BE) 2009-02-26 — — US disclosed
WO-2008006625-A2 DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR GALAPAGOS SAS (FR) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054451-A1 Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity ACKR3, CCR5, CCR7 HRH1 235/4885HTR2A 618/4885TAAR1 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback